Literature DB >> 17574273

TNF-alpha and shear stress-induced large artery adaptations.

C Keith Ozaki1, Zhihua Jiang, Scott A Berceli.   

Abstract

BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) up-regulation has been associated with both low and high shear-induced arterial remodeling. To address this apparent paradox and to define the biology of TNF-alpha signaling in large arteries, we tested the hypotheses that differential temporal expression of TNF-alpha drives shear-regulated arterial remodeling.
MATERIALS AND METHODS: Both low- and high-shear environments in the same rabbit were surgically created for common carotid arteries. Common carotid arteries (n = 60 total) were harvested after d0, d1, d3, d7, and d14 and analyses included morphology, TNF-alpha, and IL-10 mRNA quantitation. In separate experiments, animals received pegylated soluble TNF-alpha Type 1 receptor (PEG sTNF-RI) or vehicle via either short- or long-term dosing to define the effect of TNF-alpha blockade.
RESULTS: The model yielded a 14-fold shear differential (P < 0.001) with medial thickening under low shear (P = 0.025), and evidence of outward remodeling with high shear (P = 0.007). Low shear immediately up-regulated TNF-alpha expression approximately 50 fold (P < 0.001) at d1. Conversely, high shear-induced delayed and sustained TNF-alpha expression (22-fold at d7, P = 0.012; 23-fold at d14, P = 0.007). Both low and high shear gradually induced IL-10 expression (P = 0.002 and P = 0.004, respectively). Neither short-term (5-day) nor long-term (14-day) blockage of TNF-alpha signaling resulted in treatment-induced changes in the remodeling of low- or high-shear arteries.
CONCLUSIONS: Shear stress differentially and temporally regulates TNF-alpha expression in remodeling large arteries. However, TNF-alpha blockage did not substantially impact the final shear-induced morphology, suggesting that large arteries can remodel in response to flow perturbations independent of TNF-alpha signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17574273      PMCID: PMC2032015          DOI: 10.1016/j.jss.2006.12.563

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  50 in total

1.  Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb.

Authors:  M Arras; W D Ito; D Scholz; B Winkler; J Schaper; W Schaper
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

2.  Interleukin-10 inhibits human vascular smooth muscle proliferation.

Authors:  C H Selzman; R C McIntyre; B D Shames; T A Whitehill; A Banerjee; A H Harken
Journal:  J Mol Cell Cardiol       Date:  1998-04       Impact factor: 5.000

3.  Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta.

Authors:  S Jovinge; A Hultgårdh-Nilsson; J Regnström; J Nilsson
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-03       Impact factor: 8.311

4.  Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion.

Authors:  W D Ito; M Arras; B Winkler; D Scholz; J Schaper; W Schaper
Journal:  Circ Res       Date:  1997-06       Impact factor: 17.367

5.  p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.

Authors:  E Abraham; M P Glauser; T Butler; J Garbino; D Gelmont; P F Laterre; K Kudsk; H A Bruining; C Otto; E Tobin; C Zwingelstein; W Lesslauer; A Leighton
Journal:  JAMA       Date:  1997-05-21       Impact factor: 56.272

6.  Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

Authors:  K Reinhart; C Wiegand-Löhnert; F Grimminger; M Kaul; S Withington; D Treacher; J Eckart; S Willatts; C Bouza; D Krausch; F Stockenhuber; J Eiselstein; L Daum; J Kempeni
Journal:  Crit Care Med       Date:  1996-05       Impact factor: 7.598

7.  Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis.

Authors:  K Uyemura; L L Demer; S C Castle; D Jullien; J A Berliner; M K Gately; R R Warrier; N Pham; A M Fogelman; R L Modlin
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

8.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor.

Authors:  M Grell; E Douni; H Wajant; M Löhden; M Clauss; B Maxeiner; S Georgopoulos; W Lesslauer; G Kollias; K Pfizenmaier; P Scheurich
Journal:  Cell       Date:  1995-12-01       Impact factor: 41.582

9.  Proliferating arterial smooth muscle cells after balloon injury express TNF-alpha but not interleukin-1 or basic fibroblast growth factor.

Authors:  H Tanaka; G Sukhova; D Schwartz; P Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-01       Impact factor: 8.311

10.  Glycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsis.

Authors:  R Porat; H N Paddock; S D Schwaitzberg; R J Connolly; T Wilkens; J R Dasch; M P Gascon; J S Hutchison; A Ythier; D Wallach
Journal:  Crit Care Med       Date:  1995-06       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.